Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Med Res Opin ; 35(sup1): 7-8, 2019 03.
Article in English | MEDLINE | ID: mdl-30864899

ABSTRACT

The main objectives of the treatment of heart failure (HF) are to improve patient clinical status, functional capacity and quality of life, as well as reducing re-hospitalization rate and mortality. A new compound, consisting of an angiotensin-receptor blocker (ARB) (valsartan) and a neprilysin (NEP) inhibitor (sacubitril), belonging to the newly established class of angiotensin receptor-neprilysin inhibitors (ARNIs) showed marked efficacy, without any relevant safety issue, in the treatment of patients with HF. We report a case of a 48 year old male with HF with reduced ejection fraction (HFrEF) due to hypertensive cardiomyopathy (New York Heart Association [NYHA] class III). Therapy with sacubitril/valsartan was initiated after some years of other treatments, which did not lead to any positive outcome in HF, quality of life and clinical functions. After only 1 month of sacubitril/valsartan therapy, the patient reported a significant improvement in quality of life, and in 6 months his NYHA class switched from III to I.


Subject(s)
Aminobutyrates/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Heart Failure/drug therapy , Tetrazoles/therapeutic use , Biphenyl Compounds , Drug Combinations , Heart Failure/physiopathology , Heart Failure/psychology , Humans , Male , Middle Aged , Quality of Life , Stroke Volume , Valsartan
SELECTION OF CITATIONS
SEARCH DETAIL
...